GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio, Inc. (FRA:YFK) » Definitions » Debt-to-EBITDA

3SBio, (FRA:YFK) Debt-to-EBITDA : 2.32 (As of Dec. 2016)


View and export this data going back to . Start your Free Trial

What is 3SBio, Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

3SBio,'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2016 was €71.0 Mil. 3SBio,'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2016 was €348.1 Mil. 3SBio,'s annualized EBITDA for the quarter that ended in Dec. 2016 was €180.5 Mil. 3SBio,'s annualized Debt-to-EBITDA for the quarter that ended in Dec. 2016 was 2.32.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for 3SBio,'s Debt-to-EBITDA or its related term are showing as below:

FRA:YFK' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.59   Med: 1.18   Max: 2.64
Current: 2.58

During the past 13 years, the highest Debt-to-EBITDA Ratio of 3SBio, was 2.64. The lowest was 0.59. And the median was 1.18.

FRA:YFK's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.36 vs FRA:YFK: 2.58

3SBio, Debt-to-EBITDA Historical Data

The historical data trend for 3SBio,'s Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio, Debt-to-EBITDA Chart

3SBio, Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec14 Dec15 Dec16
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.46 0.59 2.64

3SBio, Semi-Annual Data
Jun06 Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.90 1.04 0.55 3.54 2.32

Competitive Comparison of 3SBio,'s Debt-to-EBITDA

For the Biotechnology subindustry, 3SBio,'s Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3SBio,'s Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio,'s Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where 3SBio,'s Debt-to-EBITDA falls into.



3SBio, Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

3SBio,'s Debt-to-EBITDA for the fiscal year that ended in Dec. 2016 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(71.028 + 348.069) / 158.75
=2.64

3SBio,'s annualized Debt-to-EBITDA for the quarter that ended in Dec. 2016 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(71.028 + 348.069) / 180.45
=2.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2016) EBITDA data.


3SBio,  (FRA:YFK) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


3SBio, Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of 3SBio,'s Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio, (FRA:YFK) Business Description

Traded in Other Exchanges
N/A
Address
3SBio Inc is engaged in the healthcare sector based in China. It is a pharmaceutical products company and its core activities pertain to developing, manufacturing and marketing biopharmaceuticals. Its portfolio of products comprises of TPIAO and Yisaipu. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world and Yisaipu is a TNF inhibibator product and accounts for the major share in the pharmaceutical industry in China. Most of the company's activities are focused on China while having a minor footprint in a foreign land.

3SBio, (FRA:YFK) Headlines

No Headlines